These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 19000488)

  • 1. [Treatment of Paclitaxel-eluting stent restenosis with sirolimus-eluting stent implantation: angiographic and clinical outcomes].
    Byrne R; Iijima R; Mehilli J; Pache J; Schulz S; Schömig A; Kastrati A
    Rev Esp Cardiol; 2008 Nov; 61(11):1134-9. PubMed ID: 19000488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis.
    Airoldi F; Briguori C; Iakovou I; Stankovic G; Biondi-Zoccai G; Carlino M; Chieffo A; Montorfano M; Cosgrave J; Michev I; Rogacka R; Sangiorgi GM; Colombo A
    Am J Cardiol; 2006 Apr; 97(8):1182-7. PubMed ID: 16616023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents.
    Kastrati A; Dibra A; Mehilli J; Mayer S; Pinieck S; Pache J; Dirschinger J; Schömig A
    Circulation; 2006 May; 113(19):2293-300. PubMed ID: 16682614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.
    Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Bruining N; Van den Branden F; Van Langenhove G
    J Am Coll Cardiol; 2006 Dec; 48(12):2423-31. PubMed ID: 17174178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus-eluting stents compared with paclitaxel-eluting stents for treatment of coronary in-stent restenoses.
    Markovic S; Paliskyte R; Rottbauer W; Wöhrle J
    Cardiovasc Revasc Med; 2012; 13(6):307-10. PubMed ID: 23164475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-eluting stent for the treatment of small coronary lesion: comparison between sirolimus- and paclitaxel-eluting stent.
    Li JJ; Xu B; Yang YJ; Chen JL; Qiao SB; Ma WH; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Gao RL
    Chin Med J (Engl); 2007 Apr; 120(7):569-73. PubMed ID: 17442204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.
    Dibra A; Kastrati A; Mehilli J; Pache J; Schühlen H; von Beckerath N; Ulm K; Wessely R; Dirschinger J; Schömig A;
    N Engl J Med; 2005 Aug; 353(7):663-70. PubMed ID: 16105990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results.
    Xu B; Dou KF; Han YL; Lü SZ; Yang YJ; Huo Y; Wang LF; Chen YD; Wang HC; Li WM; Chen JY; Wang L; Wang Y; Ge JB; Li W; Gao RL
    Chin Med J (Engl); 2011 Mar; 124(6):811-6. PubMed ID: 21518585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents.
    Kitoga M; Pasquet A; Preumont V; Kefer J; Hermans MP; Vanoverschelde JL; Buysschaert M
    Diabetes Metab; 2008 Feb; 34(1):62-7. PubMed ID: 18069029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparable clinical outcomes with paclitaxel- and sirolimus-eluting stents in unrestricted contemporary practice.
    Cosgrave J; Melzi G; Corbett S; Biondi-Zoccai GG; Agostoni P; Babic R; Airoldi F; Chieffo A; Sangiorgi GM; Montorfano M; Michev I; Carlino M; Colombo A
    J Am Coll Cardiol; 2007 Jun; 49(24):2320-8. PubMed ID: 17572247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and predictors of recurrent restenosis following implantation of drug-eluting stents for in-stent restenosis.
    Lee CW; Park CB; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2007 Jan; 69(1):104-8. PubMed ID: 17139669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
    J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term clinical outcomes after bioabsorbable polymer- and durable polymer-based sirolimus-eluting stents implantation: two-year follow-up results from a large single-center database.
    Liu HB; Xu B; Yang YJ; Wang Y; Qin XW; Yao M; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Ma WH; Li JJ; Qiao SB; Chen JL; Li W; Gao RL
    Chin Med J (Engl); 2009 Mar; 122(6):681-6. PubMed ID: 19323934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention.
    Takasawa Y; Iijima R; Shiba M; Nakamura M; Sugi K
    J Cardiol; 2010 May; 55(3):391-6. PubMed ID: 20350511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Six-month angiographic and one-year clinical outcomes of polymer free paclitaxel-eluting stent in patients with ST-segment elevation myocardial infarction: a comparison with permanent polymer sirolimus-eluting stent.
    Dang Q; Li YJ; Gao L; Jin Z; Gou LX
    Chin Med J (Engl); 2012 Oct; 125(19):3393-7. PubMed ID: 23044294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus-eluting stent showed better one-year outcomes than paclitaxel-eluting stent in a real life setting of coronary intervention in Koreans.
    Suh JW; Park JS; Cho HJ; Kim MS; Kang HJ; Cho YS; Koo BK; Chung WY; Youn TJ; Chae IH; Choi DJ; Kim HS; Sohn DW; Oh BH; Park YB
    Int J Cardiol; 2007 Apr; 117(1):31-6. PubMed ID: 17292498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymer-free sirolimus-eluting versus polymer-based paclitaxel-eluting stents: an individual patient data analysis of randomized trials.
    Cassese S; Desch S; Kastrati A; Byrne RA; King L; Tada T; Lauer B; Schömig A; Thiele H; Pache J
    Rev Esp Cardiol (Engl Ed); 2013 Jun; 66(6):435-42. PubMed ID: 24776045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction.
    Lee CW; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Yun SC; Seong IW; Lee JH; Lee NH; Cho YH; Cheong SS; Lim DS; Yang JY; Lee SG; Kim KS; Yoon J; Jeong MH; Seung KB; Hong TJ; Park SJ;
    Am J Cardiol; 2009 Nov; 104(10):1370-6. PubMed ID: 19892052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.